Navigation Links
CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
Date:6/4/2008

mmunosuppressant therapies and impairment of immune function. In

immunosuppressed patients, physicians should consider PML in the

differential diagnosis in patients reporting neurological symptoms and

consultation with a neurologist should be considered as clinically

indicated. Consideration should be given to reducing the amount of

immunosuppression in patients who develop PML. In transplant patients,

physicians should also consider the risk that reduced immunosuppression

represents to the graft.

-- CellCept can cause fetal harm when administered to a pregnant woman. A

patient who is planning a pregnancy should not use CellCept unless she

cannot be successfully treated with other immunosuppressant drugs. If

this drug is used during pregnancy, or if the patient becomes pregnant

while taking this drug, the patient should be apprised of the potential

hazard to the fetus.

-- Women of childbearing potential (including pubertal girls and

peri-menopausal women) taking CellCept must receive contraceptive

counseling and use effective contraception. The patient should begin

using her chosen contraceptive method 4 weeks prior to starting

CellCept therapy. She should continue contraceptive use during therapy

and for 6 weeks after stopping CellCept. Two reliable forms of

contraception must be used simultaneously unless abstinence is the

chosen method. Patients should be aware that CellCept reduces blood

levels of the hormones in the oral contraceptive pill and could

theoretically reduce its effectiveness.

-- Severe neutropenia [absolute neutrophil count (ANC)

<0.5 x 10cubed/microL] developed in up to 2.0% of renal, up to 2.8% of

cardiac, and up to 3.6% of hepatic transplant patients receiving

CellCept 3 g daily. Patients receiving CellCept should b
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
2. Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
3. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
4. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
5. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
6. Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
7. Reduced Lung Capacity Accelerates With Diabetes
8. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
9. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
10. Breast Cancer Treatment Is Reduced to One Week
11. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... N.J. and ANN ARBOR, Mich., Dec. 16 /PRNewswire-FirstCall/ ... ) and NanoBio Corporation today announced an exclusive ... for the over-the-counter (OTC) use of NB-001, a ... the treatment of cold sores. Developed by NanoBio, ... that causes cold sores, herpes labialis . ...
(Date:12/16/2009)... SALT LAKE CITY, Dec. 16 ... or the "Company"), a medical device company engaged ... breast ultrasound imaging system, announced today that Joe ... Board of Directors. ,, Board Chairman Ken ... to large medical devices companies, including GE OEC ...
(Date:12/16/2009)... Texas, Dec. 16 Savara, Inc., an inhalation ... the second tranche in its Series A financing round, ... ,, Funds raised in the Series A ... the NanoCluster technology. ,, "We now have the ... performance of the NanoCluster technology," said Rob Neville, CEO ...
Breaking Medicine Technology:GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent 2International Design Team Selected for Nigerian Hospital 54514 1International Design Team Selected for Nigerian Hospital 54514 2Spain Has The 26apos 3BStress 26apos 3B Factor According to Confused com 54509 1Spain Has The 26apos 3BStress 26apos 3B Factor According to Confused com 54509 2Spain Has The 26apos 3BStress 26apos 3B Factor According to Confused com 54509 3First 5 California Approves 2481 4 Million Contribution to Help Restore Healthy Families Programs Viability 54507 1First 5 California Approves 2481 4 Million Contribution to Help Restore Healthy Families Programs Viability 54507 2
... Dept. of Defense Continues Study of Copper as ... and Improving Indoor Air Quality, NEW YORK, ... trails determining the,antimicrobial effectiveness of copper, brass and ... announced CDA President Andrew G.,Kireta Sr. Of ...
... Tolerance with No Serious Adverse Reactions, BERKELEY ... GNTA ) released findings from the initial clinical,dosing ... is intended,as a treatment for diseases associated with ... conducted in normal volunteers, has shown good,tolerance with ...
Other Medicine Technology:Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 2Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 2Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 4Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 5
(Date:12/16/2009)... Retirement Services Division has announced plans to introduce ... 2010. The new platform will include a full ... in a variety of themes. Plan sponsors will ... of creative options to support the theme best ... RetireSmart participant engagement platform will be phased in ...
(Date:12/16/2009)... Boston University School of Medicine,s (BUSM) Pulmonary Center ... the National Heart, Lung, and Blood Institute to ... with lung disease. , Darrell Kotton, MD, ... Mostoslavsky, MD, PhD, assistant professor of medicine, are ... Together Kotton and Mostoslavsky lead a multicenter investigative ...
(Date:12/16/2009)... Solutions, a national healthcare staffing agency, is honored to announce ... the company’s Recruiters of the Year in Healthcare Traveler magazine’s ... consecutive year that Chris has received such honors and the ... ... December 16, 2009 -- Medical Solutions, a national healthcare staffing ...
(Date:12/16/2009)... 16 Medizone International, Inc. (OTC Bulletin ... of Directors and the Board of Medizone New ... International Inc. holds a 50% interest, agreed on ... and reconvey to Medizone International all global marketing ... International,s Chairman, Edwin G. Marshall said, "Time has ...
(Date:12/16/2009)... risks , , TUESDAY, Dec. 15 (HealthDay News) -- If ... impact on your life that you just can,t wait to ... that you might want to wait at least six months ... could be even better. , The study found that ... the chances of the baby dying, being born prematurely, having ...
Breaking Medicine News(10 mins):Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 3Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 4Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 5Health News:Boston University School of Medicine's pulmonary center receives $1.4 million grant 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 3Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3
... ELMWOOD PARK, N.J., July 2 PhytoCeuticals, Inc., ... care,formulations, who is the Fast to invent Stable ... granting IS Clinical from,Innovative Skin Care the right ... Inc. effective July 1, 2008., The IS ...
... 2 FGX International,(Nasdaq: FGXI ), a ... and costume jewelry, today announced that Alec Taylor,Chief ... Chief,Financial Officer will be presenting at the Oppenheimer ... 2008 at The Four Seasons Hotel in,Boston., ...
... recent rises in caesarean section rates, according to a ... , The findings come from an analysis of a ... under Professor Gordon Smith, at the University,s Department of ... than 500,000 entries collected by the Scottish Morbidity Record ...
... be viewed as a safe alternative to smoking, experts say ... (STPs), which include products such as snuff and chew tobacco, ... not as much as smoking does. , So say researchers ... risk of cancer. , Reporting in the July issue of ...
... Study suggests explanation for these practices, health benefits , , ... taken a significant stride forward in understanding how relaxation ... by changing patterns of gene activity that affect how ... seen both in long-term practitioners and in newer recruits, ...
... SUPG ), a pharmaceutical company dedicated to ... solid tumors and,hematological malignancies, today announced that James ... scheduled to present at the,Collins Stewart Growth Conference ... Hotel in New York City., SuperGen,s presentation ...
Other Medicine News:Health News:Termination of IS Clinical From Distributing PhytoCeuticals Formulas 2Health News:Major rise in Caesarean sections linked to impaired womb function with age 2Health News:Smokeless Tobacco Products Do Raise Cancer Risk 2Health News:Meditation, Yoga Might Switch Off Stress Genes 2Health News:Meditation, Yoga Might Switch Off Stress Genes 3Health News:SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008 2
...
... easy-to-operate, semi-automatic urine analyzer that ensures accurate ... lab efficiency by reducing "hands on" operator ... it an ideal fit for work areas ... II Analyzer is designed for continuous sample ...
... are positioned in a burr ... of brain activity. They have ... in several lengths to accommodate ... mm twist drill is suitable ...
... electrodes are extra thin and flexible ... burr hole. The narrow cylindrical connector ... and secure attachment to the patented ... electrode designs, they are available with ...
Medicine Products: